Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Kim, Young Il ^a   Park, Joong Won ^a   Kim, Bo H ^a   Woo, Sang M ^a   Kim, Tae H ^a   Koh, Young H ^a   Lee, Woo J ^a   Kim, Chang Min ^a  

^a National Cancer Center   (South Korea)

Author keywords

Chemoradiotherapy; Cholangiocarcinoma; Intrahepatic; Unresectable

Indexed keywords

CAPECITABINE; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL FEATURE; COMPARATIVE STUDY; DRUG TOLERABILITY; DYSPNEA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; INOPERABLE CANCER; KOREA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CHOLANGIOCARCINOMA; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84890517686     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-292     Document Type: Article

References (31)

1. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011, 8:512-522. 10.1038/nrgastro.2011.131, 3331791, 21808282.
2. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001, 33:1353-1357. 10.1053/jhep.2001.25087, 11391522.
3. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999, 341:1368-1378. 10.1056/NEJM199910283411807, 10536130.
4. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P, Thomas HC. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001, 48:816-820. 10.1136/gut.48.6.816, 1728314, 11358902.
5. Patel T. Cholangiocarcinoma-controversies and challenges. Nat Rev Gastroenterol Hepatol 2011, 8:189-200. 10.1038/nrgastro.2011.20, 21460876.
6. Morise Z, Sugioka A, Tokoro T, Tanahashi Y, Okabe Y, Kagawa T, Takeura C. Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol 2010, 2:58-64. 2998957, 21160974.
7. Yedibela S, Demir R, Zhang W, Meyer T, Hohenberger W, Schonleben F. Surgical treatment of mass-forming intrahepatic cholangiocarcinoma: an 11-year Western single-center experience in 107 patients. Ann Surg Oncol 2009, 16:404-412. 10.1245/s10434-008-0227-1, 19037702.
8. Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001, 193:384-391. 10.1016/S1072-7515(01)01016-X, 11584966.
9. Puhalla H, Schuell B, Pokorny H, Kornek GV, Scheithauer W, Gruenberger T. Treatment and outcome of intrahepatic cholangiocellular carcinoma. Am J Surg 2005, 189:173-177. 10.1016/j.amjsurg.2004.11.009, 15720985.
10. Park J, Kim MH, Kim KP, Parks H, Moon SH, Song TJ, Eum J, Lee SS, Seo DW, Lee SK. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 2009, 3:298-305. 10.5009/gnl.2009.3.4.298, 2852727, 20431764.
11. Gebbia V, Majello E, Testa A, Pezzella G, Giuseppe S, Giotta F, Riccardi F, Fortunato S, Colucci G, Gebbia N. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Cancer 1996, 78:1300-1307. 10.1002/(SICI)1097-0142(19960915)78:6<1300::AID-CNCR19>3.0.CO;2-4, 8826954.
12. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996, 7:593-600. 10.1093/oxfordjournals.annonc.a010676, 8879373.
13. Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B, McCashland T, Sorrell M, Tempero M, Langnas A. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002, 2:774-779. 10.1034/j.1600-6143.2002.20812.x, 12243499.
14. De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, Burgart L, Gores GJ. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver transpl 2000, 6:309-316. 10.1053/lv.2000.6143, 10827231.
15. Hong JC, Jones CM, Duffy JP, Petrowsky H, Farmer DG, French S, Finn R, Durazo FA, Saab S, Tong MJ, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 2011, 146:683-689. 10.1001/archsurg.2011.116, 21690444.
16. Hong JC, Petrowsky H, Kaldas FM, Farmer DG, Durazo FA, Finn RS, Saab S, Han SH, Lee P, Markovic D, et al. Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma. J Am Coll Surg 2011, 212:514-520. 10.1016/j.jamcollsurg.2010.12.005, 21463781.
17. Foo ML, Gunderson LL, Bender CE, Buskirk SJ. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 1997, 39:929-935. 10.1016/S0360-3016(97)00299-X, 9369143.
18. Deodato F, Clemente G, Mattiucci GC, Macchia G, Costamagna G, Giuliante F, Smaniotto D, Luzi S, Valentini V, Mutignani M, et al. Chemoradiation and brachytherapy in biliary tract carcinoma: long-term results. Int J Radiat Oncol Biol Phys 2006, 64:483-488. 10.1016/j.ijrobp.2005.07.977, 16242254.
19. Edge SB. American Joint Committee on Cancer: AJCC cancer staging manual 2009, New York: Springer.
20. Shim JH, Park JW, Nam BH, Lee WJ, Kim CM. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009, 63:459-467. 10.1007/s00280-008-0759-x, 18437384.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
22. Liver Cancer Study Group of Japan The general rules for the clinical and pathological study of primary liver cancer 2000, Tokyo: Kanehara, 4, Liver Cancer Study Group of Japan.
23. McMasters KM, Tuttle TM, Leach SD, Rich T, Cleary KR, Evans DB, Curley SA. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997, 174:605-608. 10.1016/S0002-9610(97)00203-1, 9409582.
24. Brunner TB, Eccles CL. Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma. Strahlenther Onkol 2010, 186:672-680. 10.1007/s00066-010-2161-y, 21136029.
25. Crane CH, Macdonald KO, Vauthey JN, Yehuda P, Brown T, Curley S, Wong A, Delclos M, Charnsangavej C, Janjan NA. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 2002, 53:969-974. 10.1016/S0360-3016(02)02845-6, 12095564.
26. Chen YX, Zeng ZC, Tang ZY, Fan J, Zhou J, Jiang W, Zeng MS, Tan YS. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer 2010, 10:492. 10.1186/1471-2407-10-492, 2949805, 20840777.
27. Poultsides GA, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am 2010, 90:817-837. 10.1016/j.suc.2010.04.011, 20637950.
28. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362:1273-1281. 10.1056/NEJMoa0908721, 20375404.
29. Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol 2007, 60:321-328. 10.1007/s00280-006-0380-9, 17143602.
30. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, Kim JH, Lee JS, Kang YK. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003, 14:1115-1120. 10.1093/annonc/mdg281, 12853355.
31. Vaishampayan UN, Ben-Josef E, Philip PA, Vaitkevicius VK, Du W, Levin KJ, Shields AF. A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys 2002, 53:675-679. 10.1016/S0360-3016(02)02772-4, 12062611.